What Happens When Tirzepatide Stops? SURMOUNT-4, SURMOUNT-MAINTAIN and the Weight-Regain Evidence
Randomised withdrawal and maintenance trials of tirzepatide: weight regain, cardiometabolic reversal and step-down data. Lab research only.
Randomised withdrawal and maintenance trials of tirzepatide: weight regain, cardiometabolic reversal and step-down data. Lab research only.
Copper(II) coordination in GHK-Cu, speciation and albumin exchange, and what HPLC, MS and copper-specific tests can show. Lab research only.
How MOTS-c compares with humanin and SHLPs: discovery, mtDNA open reading frames, receptors versus nuclear signalling, variants. Lab research only.
Comparing GLP-1, GIP/GLP-1 and GIP/GLP-1/glucagon agonist research, why cross-trial comparisons are limited and where head-to-head data exist. Lab only.
How extracellular NAD+ reaches cells and mitochondria: CD38/CD73 ectoenzymes, the disputed Slc12a8 NMN transporter and SLC25A51. Lab research only.
What studies show about combining BPC-157, TB-500 and GHK-Cu, copper chemistry, oxidation and what a blend study would need. Lab research only.
Preclinical BPC-157 cytoprotection, NSAID and alcohol gastric models, fistulas and anastomoses, plus thymosin β4 gut findings. Lab research only.
What randomised trials report about tesamorelin or GHRH analogues, cognition, brain GABA and HIV-associated neurocognitive impairment. Lab research only.
How Phase 1–3 studies describe tirzepatide gastric emptying, appetite scores and energy intake versus selective GLP-1 agonists. Lab research only.
How cell and mouse studies link MOTS-c to the folate cycle, AMPK, nuclear gene regulation, CK2 and exercise in muscle. Lab research only.